Our 2nd Annual Committee Summit takes place in London today, where we’ll be hearing from each of our eight Advisory Committees on their 2015 objectives and key issues and priorities for 2016. Here we take a look at our Committees focussing on the fields of synthetic biology and cell therapy and regenerative medicine, two areas identified by policy makers as technologies in which the UK is set to be a global leader – part of the “Eight Great Technologies” initiative. Find out more in these infographics: synthetic biology and regenerative medicine.
Cell Therapy and Regenerative Medicine Advisory Committee (CTRMAC)
CTRMAC is one of our most popular committees with over 30 member companies taking part, many of which are involved in the R&D of cell and gene therapies. In 2015 the Committee welcomed Cell Medica and Cellular Therapeutics into the fold.
The Committee maintains close links to the wider cell therapy and regenerative medicine sector – the newly renamed Cell and Gene Therapy Catapult hosts the majority of CTRMAC meetings and through the year we’ve had guest speakers from the ATMP Manufacturing Community (amc) and UK Regenerative Medicine Platform (UKRMP).
In 2016 the Committee will be working in alignment with our Regulatory Affairs Advisory Committee priorities in reviewing NICE’s forthcoming mock appraisal of a CAR-T cell therapy, and will align with manufacturing issues and the Manufacturing Advisory Committee regarding the supply chain of viral vectors for gene therapy. Once the Accelerated Access Review report is released this spring, CTRMAC will focus on the implications for cell and gene therapies, particularly on pricing and reimbursement of advanced therapy medicinal products (ATMPs).
Synthetic Biology Advisory Committee (SBAC)
In 2015 we were pleased to welcome SynbiCITE, the Innovation and Knowledge Centre for Synthetic Biology, as a new member of both BIA and SBAC. For the third year running, a number of SBAC members (this year Synpromics, Synthace, Touchlight Genetics and ZuvaSyntha) were represented on UK trade mission to San Francisco, organised and funded by SynbiCITE with UKTI support.
Following on from the 2012 UK Roadmap for Synthetic Biology, the Synthetic Biology Leadership Council, with ministerial level input, has this week published the next phase of strategic direction for this growing technology area – Biodesign for the Bioeconomy: UK Synthetic Biology Strategic Plan 2016.
Speaking at the launch of the plan yesterday, Life Sciences Minister George Freeman MP outlined a vision for the growth of this innovative sector in the UK, ensuring the UK maintains its position as a global leader. In conjunction with this, SBAC’s core aims in 2016 include to continue to showcase strengths in the UK sector, which is likely to include company engagement at the popular SynBioBeta conferences in London (6 – 8 April 2016) and San Francisco, and to increase investor awareness of and engagement with UK synthetic biology.